A deeper understanding of the multifaceted roles of monocytes and macrophages in IIM pathogenesis is paving the way for ... mesenchymal stem cell-derived exosomes (MSC-Exos), JAK inhibitors, ...
Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...
Saphnelo (anifrolumab) is the first biologic drug for SLE to be approved in Europe that is not restricted to patients with a high degree of disease activity, according to AZ, which also notes it ...
The amelioration of the B cell immunity signature across diverse treatments emphasises the key role of B cells in the pathogenesis of SLE through autoantibody production and antibody-independent ...
Despite advancements in the management of systemic lupus erythematosus (SLE), patients experience poor health-related quality of life (hrQoL) and premature death due to disease severity and treatment ...
Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC ...
Treatment and lifestyle change recommendations by cardiologist for patients attending cardiology outpatient clinics: a TLC study Advances in Interventional Cardiology 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback